NCT01255137View on ClinicalTrials.gov

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Adrenal Cortex Neoplasms

Interventions

DRUG

Axitinib

5 mg tab orally twice a day with food every 28 days

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

National Cancer Institute (NCI)

NIH